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Malaria is one of the three most hazardous infectious dis-
eases (HIV/AIDS, Malaria and tuberculosis) in the world. 
Since 1960, falciparum malaria gradually became resistant 
to original antimalarial drugs such as Chloroquine and Fan-
sidar. With the global spread of drug-resistant falciparum 
malaria, morbidity and mortality increased greatly. In May 
of 2014, the World Health Organization (WHO) announced 
that the drug combination with artemisinin-based compound 
is by far the only effective drug around the world in the 
treatment of falciparum malaria.  
In October 1974, when whether or not Qinghaosu affects 
falciparum malaria was known, the National Head Office of 
523 Project requested Guoqiao Li’s team to perform a clin-
ical trial with Huanghaosu (Artemisia scoparia) tablets (re-
named as Qinghaosu after 1978) produced by the Yunnan 
Institute of Materia Medica. Li’s team tested the drug on 14 
falciparum malaria cases (including 3 cases of cerebral ma-
laria) and 4 cases of vivax malaria from October to Decem-
ber of 1974. This was the first study to show the effective-
ness of Qinghaosu (artemisinin) against falciparum malaria 
(Li et al., 2015). Based on these results, a nationwide col-
laborative research on the antimalarial Qinghaosu was con-
ducted in April 1975. In 1978, China succeeded in antima-
larial studies on Qinghaosu. This success offered a new 
hope for the treatment of drug-resistant falciparum malaria. 
The 1984 article in The Lancet “A randomized comparative 
study of mefloquine, Qinghaosu and pyrimetham-
ine-sulfadoxine in patients with falciparum malaria” by 
Guoqiao Li, Keith Arnold (Director of Roche Fareast Re-
search Foundation based in Hong Kong), Xingbo Guo et al 
was the first to use an artemisinin-based combination in 
treating falciparum (Li et al., 1984). 
The first generation of artemisinin-based compound- 
piperquine phosphate tablet, researched and developed by 
Guangzhou University of Traditional Chinese Medicine, 
was registered and produced in Vietnam in 1997 (Brand 
name “Malaria Tablet CV8” in Vietnam). As a frontline 
antimalarial drug, Malaria Tablet CV8 was sent, at no cost, 
to primary level hospitals and clinics in malaria-epidemic 
districts in Vietnam in 1999. This action gained great atten-
tion by the WHO. Since then, Prof. Li’s team has developed 
and optimized several artemisinin-based compounds as new 
antimalarial drugs. Among them, new drug certifications for 
double hydrogen artemisinin-piperaquine phosphate tablet 
(Brand name Artekin) and artemisinin-piperaquine (Brand 
name Artequick, Yuetekuai) were issued in 2003 and 2006, 
respectively. Both were included in The Principle and 
Scheme for the Use of Antimalarial Drugs in 2009. Artekin 
was also included in the second edition of the WHO Guide-
lines for the treatment of malaria (March 2010). 
In 2003, after reviewing the antimalarial history and the 
past 50 plus years’ experience in China, Guoqiao Li sug-
gested that the antimalarial strategy should be changed from 
eradicating the mosquito vector to eradicating the infectious 
source (malaria parasites) in the parasite-carrying patients 
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or asymptomatic carriers. The new approach “Fast Elimina-
tion of Malaria by Source Eradication” (FEMSE) is capable 
of eradicating malaria in an area of one million plus popula-
tion within two years, compared to the fifty to sixty years 
needed in the past. 
In June 2003, the project leader signed a collaborative 
agreement on “fast control and elimination of malaria” with 
the national malaria center of Cambodia. To rapidly elimi-
nate the infectious source, they successively carried out 
mass drug administration (MDA) from 2004~2006, using 
the artemisinin-based compound “Yuetekuai”, plus a 9mg 
single dose of Primaquine. These administrations were car-
ried out at 3 pilot sites where the G6PD deficiency rate was 
as high as 14.7%, with populations of 7,000; 3,000; and 
18,000 respectively. These studies revealed quick-acting, 
safe and good results. Thus, the new approach, FEMSE, 
was proven to be effective. 
Li’s team transferred to Comoros, Africa at the end of 
2006. After one year’s malaria prevalence investigation and 
preparation, FEMSE was again carried out in Nov, 2007 on 
Moheli island which had a population of 36,000 at a high 
G6PD deficiency rate of 15.1%. This treatment led to more 
significant effects than those in Cambodia. After 4 months’ 
implemention, the plasmodium carrier rate in the population 
decreased from 23.0% to 0.33%, and the plasmodium carri-
er positive rate in the mosquito vector declined from 3.1% 
(8/258) to 0% (0/400, 0/517). Death by malaria was 
stopped. This confirmed that the approach of eradication of 
infectious source and elimination of malaria was feasible for 
the rapid control of malaria. MDA was implemented in An-
jouan island (with a population of 350,000) in October, 
2012, and in the Grand Comoros (with a population of 
400,000) from October to December, 2013. During one year 
of implemention of FEMSE on these two islands, malaria 
prevalence was effectively restrained, and parasite carrier 
rate and morbidity both declined by 95%. Nationwide mor-
bidity in the 2nd year deceased to 2.8‰ (close to the control 
level). Comoros was changed from a high to a low malaria 
epidemic area within a short time and the expected goal of 
no malaria-induced death was achieved. 
To clearly define the necessary steps in the rapid control 
and elimination of malaria, Prof. Li’s team has pursued 
studies on rapid elimination of infectious source. After 12 
years’ continuous improvement, Prof. Li summarizes the 
following three major steps in FEMSE (Figure 1) to achieve 
rapid malaria elimination as follows: (i) Rapid malaria con-
trol relies on two rounds of MDA to the whole population 
with a high coverage rate (Li et al., 2010, 2015). (ii) Rapid 
malaria eradication relies on mass screening with polymer-
ase chain reaction (PCR) technique for remnant infectious 
source detection and source elimination by treating all PCR 
positive individuals (Li et al., 2013). (iii) Thorough malaria 
infectious source eradication relies on the early diagnosis 
and early treatment policy and on joint action among  
 
Figure 1 (color online)  Three major steps in FEMSE to achieve rapid 
malaria elimination. PR, parasite rate; Rec, recrudescence; Rei, reinfection; 
P. falciparum, Plasmodium falciparum; P. vivax, Plasmodium vivax. 
neighboring districts against malaria re-entry. 
PCR technique has been around for more than twenty 
years, and has been widely applied in the biologic and sci-
entific fields. From 2007to2013, we found the key reactive 
agent and optimized the detection method. Thus, we simpli-
fied the PCR operational procedure and lowered the cost, 
making PCR applicable for mass population screening in 
the FEMSE approach. This is a breakthrough in solving the 
difficult problem of the lingering low or re-surging popula-
tion parasite carrier rate noted in the disappointing global 
antimalarial history. MDA was carried out on two large 
islands in 2012 and 2013. This action decreased the chance 
of transmission by migration to Comoros. We performed 
PCR mass screening in eleven selected villages on Moheli 
Island of Comoros in October of 2013. These villages were 
chosen because they had a few malaria cases in the previous 
two years. A total of 5,911 villagers were tested, and the 
PCR positive cases were numbered at 200 and the PCR pos-
itive rate was 3.4%. These carriers were treated 3 days with 
an artemisinin-based combination plus a low dose of 8mg 
primaquine added to the first dose. These drugs were dis-
pensed by the antimalarial sub-center of the village and 
again sent by VMW to be taken by positive individuals. The 
PCR negative conversion rates were 92.7%, 93.9% and 
100% respectively by days 5, 7 and 10. The results in 2013 
suggested that the fastest and least costly technology to 
solve the problem of lingering low or re-surging population 
parasite carrier rate is to detect the infectious source and 
eliminate the infectious source by PCR. This technology 
creates an important condition for the rapid elimination of 
malaria. 
After the implementation of FEMSE in a malar-
ia-epidemic country or district (except for areas of political 
turmoil and civil war), the prevalence of malaria can be 
quickly controlled within half a year, death of malaria can 
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be stopped, and malaria can be expected to be eradicated 
within 2 years. Therefore FEMSE plays an important role in 
quickly suppressing and eradicating the first killer, malaria.  
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